AG
Anne Goffard Portfolio
Invests via Artal Group S.A. | Managed by Anne Goffard
Invests via Artal Group S.A.
Managed by Anne Goffard
Automatically Tracked
Anne Goffard Profile
With a robust background in investment management, Anne Goffard has distinguished herself as a dynamic leader in the finance sector. Her career encompasses roles that highlight expertise in operational excellence and strategic initiatives across multiple market environments. Leveraging her experience, she contributes to enhancing organizational efficiencies while navigating complex business landscapes. Known for fostering collaborative relationships within the industry, her ability to drive performance outcomes and develop talent underlines her significance as a trailblazer in corporate leadership. As trends evolve, Goffard remains at the forefront of investment solutions relevant to contemporary markets.
With a robust background in investment management, Anne Goffard has distinguished herself as a dynamic leader in the finance sector. Her career encompasses roles that highlight expertise in operational excellence and strategic initiatives across multiple market environments. Leveraging her experience, she contributes to enhancing organizational efficiencies while navigating complex business landscapes. Known for fostering collaborative relationships within the industry, her ability to drive performance outcomes and develop talent underlines her significance as a trailblazer in corporate leadership. As trends evolve, Goffard remains at the forefront of investment solutions relevant to contemporary markets.
Investment Philosophy & Strategy
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
97.21%
Gain -35.35%
Monthly
-0.2%
Yearly
-2.4%
Drawdown
95.02%
$2.46B
Equity
Holdings
$2.46B
Investment
$3.12B
$940.25M
Profit -$826.04M
Realized
$1.59B
Unrealized
-$652.08M
Dividends
$89.68M
Goals
Avg. 0% completed goals
Today
Compared To Yesterday
Gain
-35.35%
Profit
-$826.04M
Win %
52%
This Week
Compared To Last Week
Gain
-28.71%
Profit
-$992.03M
Win %
52%
This Month
Compared to last month
Gain
-28.99%
Profit
-$1.01B
Win %
52%
This Year
Compared to last year
Gain
-22.26%
Profit
-$185.13M
Win %
53%
CPAC Cementos Pacasmayo S.A.A. - ADR
+1.4%
+$57,655.5 
VIPS Vipshop Holdings Ltd - ADR
+1.31%
+$1.47M 
CAVA Cava Group Inc.
+0.76%
+$2.54M 
YPF YPF S.A. Sponsored ADR
+0.4%
+$132,000 
IRWD Ironwood Pharmaceuticals Inc.
+0.35%
+$3,884.3 
HCA HCA Healthcare Inc.
+0.19%
+$164,998.2 
BMRN Biomarin Pharmaceutical Inc.
+0.03%
+$6,999.3 
MTOR Meritor Inc
+0.03%
+$17,500 
BZH Beazer Homes USA Inc.
+0.01%
+$500 
ACOR Acorda Therapeutics Inc
0%
$0 
IMGN ImmunoGen Inc
0%
$0 
SLCA US Silica Holdings Inc
0%
$0 
XOMA XOMA Corporation
0%
$0 POT
POT
0%
$0 ESRX
ESRX
0%
$0 ONXX
ONXX
0%
$0 WW
WW
0%
$0 AUXL
AUXL
0%
$0 AMRN
AMRN
0%
$0 ARRY
ARRY
0%
$0 SMT
SMT
0%
$0 CERE
CERE
0%
$0 CJES
CJES
0%
$0 CPRH
CPRH
0%
$0 FURX
FURX
0%
$0 AGEN
AGEN
0%
$0 AVNR
AVNR
0%
$0 BIOD
BIOD
0%
$0 
AFFX Affymetrix, Inc.
0%
$0 5949
594960163
0%
$0 
BRFS BRF S.A. ADR
-11.52%
-$294,800 
NG NovaGold Resources Inc.
-2.83%
-$315,000 
LAB Standard Biotools Inc.
-2.4%
-$5,475.74 
ITUB Itaú Unibanco Holding S.A. Sponsored Preferred ADR
-1.75%
-$563,854.9 
LXRX Lexicon Pharmaceuticals, Inc.
-1.23%
-$5.27M 
PACB Pacific Biosciences of California, Inc.
-1.09%
-$3,000 
AAPL Apple Inc.
-1.04%
-$981,400 
ARCO Arcos Dorados Holdings Inc.
-0.79%
-$52,386.28 
LAMR Lamar Advertising Company
-0.73%
-$321,960 
NKTR Nektar Therapeutics Inc.
-0.69%
-$129,109 
MET MetLife Inc.
-0.63%
-$581,757 
MS Morgan Stanley
-0.32%
-$325,000 
BAC Bank of America Corporation
-0.07%
-$32,000 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 2247 | Longs Won 1015/2247 45% | Profit Factor 1.14 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $53.29M |
| Average Win $7.42M | Best Trade (Jun 29) $1.92B | Sharpe Ratio -122.57 |
| Average Loss -$5.35M | Worst Trade (Aug 14) -$933.1M | Z-Score -2.96 (100%) |
| Commissions $0 | Avg. Trade Length 1y 11m 3w 5d | Expectancy $418,448.08 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | - | - | - | - | - | - | - | - | - | - |
| Consecutive Losing Trades | 460 | 414 | 368 | 322 | 276 | 230 | 184 | 138 | 92 | 46 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 5949 594960163 | 360,515 | $13,999.99 | $11,000 | - | -$2,999.99 | -21.43% | 0.0 |
| AAPL Apple Inc. | 280,000 | $5.98M | $93.38M | - | $87.4M | 1,460.67% | -1.04% |
| ACOR Acorda Therapeutics Inc | 12,316.25 | $38.96M | $409,884.8 | - | -$38.55M | -98.95% | 0.0 |
| AFFX Affymetrix, Inc. | 2.75M | $9.11M | $17.04M | - | $7.93M | 87.1% | 0.0 |
| AGEN AGEN | 410,130 | $623,385.09 | $237,875.4 | - | -$385,509.69 | -61.84% | 0.0 |
| AMRN AMRN | 825,000 | $6.67M | $6.11M | - | -$561,000 | -8.4% | 0.0 |
| ARCO Arcos Dorados Holdings Inc. | 873,104.7 | $10.17M | $6.61M | - | -$3.55M | -34.95% | -0.786% |
| ARRY ARRY | 2.8M | $31.25M | $68.26M | - | $37.01M | 118.44% | 0.0 |
| AUXL AUXL | 2.15M | $40.2M | $64.17M | - | $23.97M | 59.61% | 0.0 |
| AVNR AVNR | 3.1M | $12.07M | $36.95M | - | $24.88M | 206.07% | 0.0 |
| BAC Bank of America Corporation | 800,000 | $10.91M | $46.51M | - | $35.6M | 326.25% | -0.069% |
| BIOD BIOD | 290,740 | $683,000.01 | $916,000.01 | - | $233,000 | 34.11% | 0.0 |
| BMRN Biomarin Pharmaceutical Inc. | 350,000 | $27.6M | $22.79M | - | -$4.82M | -17.45% | +0.031% |
| BRFS BRF S.A. ADR | 670,000 | $13.34M | $2.26M | - | -$11.07M | -83.02% | -11.518% |
| BZH Beazer Homes USA Inc. | 100,000 | $1.69M | $3.33M | - | $1.64M | 97.37% | +0.015% |
| CAVA Cava Group Inc. | 6.51M | $266.5M | $335.81M | - | $69.31M | 26.01% | +0.762% |
| CERE CERE | 4.55M | $6.01M | $1.5M | - | -$4.51M | -75.03% | 0.0 |
| CJES CJES | 197,860 | $3.66M | $3.66M | - | - | - | 0.0 |
| CPAC Cementos Pacasmayo S.A.A. - ADR | 339,150 | $4.47M | $4.17M | - | -$290,910.9 | -6.51% | +1.4% |
| CPRH CPRH | 43,000 | $3.68M | $3.68M | - | - | - | 0.0 |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Anne Goffard?
The largest contributions to the portfolio's profits come from the following stocks: BUFF - $2.08B, Cava Group Inc - $1.5B, Moderna, Inc - $184.81M, Acceleron Pharma Inc - $182.31M, and BioNTech SE - $136.95M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Lexicon Pharmaceuticals, Inc - $844.58M, WW International, Inc - $499.38M, Seer, Inc - $278.35M, Mirati Therapeutics Inc - $164.09M, and Igm Biosciences Inc - $112.88M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Anne Goffard's portfolio generate?
The portfolio generates substantial dividend income, with a total of $89.68M earned over time. The largest contributors to dividend income include MetLife Inc - $16.92M, Lamar Advertising Company - $15.26M, Vipshop Holdings Ltd - ADR - $14.09M, Morgan Stanley - $13.16M, and Bank of America Corporation - $6.89M. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Anne Goffard's monthly returns?
Anne Goffard's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can Anne Goffard's strategy be considered aggressive or moderate?
Anne Goffard's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow Anne Goffard's strategy?
Anne Goffard's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
